Voyager Therapeutics operates at the intersection of gene therapy innovation and clinical-stage risk, deploying its TRACER™ platform to enhance blood-brain barrier crossing for CNS-targeted treatments. Despite notable technological differentiation and strategic partnerships delivering milestone payments, the company’s financials reveal a pronounced deterioration with mounting operating losses and negative operating cash flow as development costs accelerate. Upcoming clinical trial readouts and collaboration milestones shape near-term catalysts, but funding needs and regulatory uncertainties represent key challenges ahead.